跳至主要内容
临床试验/ACTRN12620001098921
ACTRN12620001098921尚未招募未知

Prospective, Multi-centre Study to Assess Efficacy (Survivorship) of the Mpact 3D Metal MonoCer Cup Implant in Primary Total Hip Replacement

Medacta Australia Pty Ltd0 个研究点目标入组 280 人开始时间: 2020年10月21日最近更新:
适应症

试验速览

阶段
未知
状态
尚未招募
入组人数
280

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 Years 至 75 Years(—)
性别
All

入选标准

  • Patients undergoing a primary total conventional hip replacement and are suitable for a cementless acetabular cup according to the indications for use (On-label use).
  • - Use of the non TGA approved (pre-market) Medacta Mpact 3D Metal MonoCer acetabular cup prosthesis.
  • - Adults aged between 18 and 75 years at the time of registration.
  • - Ability to give informed consent.
  • - Patients who are informed of the conditions of the study and are willing to participate for the length of the prescribed follow-up period.

排除标准

  • - Rheumatoid arthritis.
  • - Patients with a history of active infection.
  • - Any case not described in the inclusion criteria.
  • - Revision procedures.

研究者

相似试验